This school year is the first time boys will be offered the HPV...
- Expanding HPV vaccination to boys: what more needs to be done?
- Queen’s Speech 2019: UK seeks to strengthen NHS and life sciences
- UK Government invests £35m into researching adolescent mental health
- J&J resolves opioid lawsuits in two Ohio counties for $20.4m
- Avanir resolves Nuedexta kickback lawsuits for $116m
Expanding HPV vaccination to boys: what more needs to be done?
This school year is the first time boys will be offered the HPV vaccination in the UK. However, unlike the existing programme for girls where the HPV vaccine is available for free until the age of 25, it will only be offered to boys aged 12 to 13. Representatives for HPV Action and Teenage Cancer Trust argue that this is insufficient to fully protect boys from the cancers caused by HPV infections and are calling for older boys to also be included in the UK’s immunisation programme.
Queen’s Speech 2019: UK seeks to strengthen NHS and life sciences
In the first Queen’s Speech since the UK began negotiating Brexit with the EU, the UK Government laid out, among other things, its commitments to supporting and strengthening the life sciences sector in general, and specifically healthcare, where it will focus on achieving the aims of the NHS Long Term Plan and reforming the Mental Health Act. How have experts responded to these new policy initiatives?
Xarelto gets approval to prevent blood clots in acutely ill patients
Janssen Pharmaceutical has received the US Food and Drug Administration (FDA) approval for Xarelto (rivaroxaban) to prevent venous thromboembolism (VTE) or blood clots.
Lilly receives FDA approval for migraine drug Reyvow
Eli Lilly has obtained the US Food and Drug Administration (FDA) approval for Reyvow in the acute treatment of adults suffering from migraine, with or without aura.
NICE approves Clovis Oncology’s rucaparib for CDF use
The National Institute for Health and Care Excellence (NICE), UK has approved Clovis Oncology’s ovarian cancer drug rucaparib (Rubraca) for use within the Cancer Drugs Fund (CDF).
Boehringer’s nintedanib secures breakthrough status in US for ILDs
Boehringer Ingelheim has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for nintedanib in chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
Clinuvel obtains US approval for rare disorder drug Scenesse
Australia-based Clinuvel Pharmaceuticals has received the US Food and Drug Administration (FDA) approval for the use of Scenesse (16mg afamelanotide) to treat erythropoietic protoporphyria (EPP), which results in absolute intolerance to light.
AirBridgeCargo Airlines is Re-Certified for IATA CEIV Pharma
AirBridgeCargo Airlines has successfully gained its IATA CEIV Pharma re-certification following two-day audit procedures for compliance with IATA’s Center of Excellence for Validators in Pharmaceutical Logistics (CEIV Pharma) certification program.
Novartis receives FDA approval for Beovu to treat wet AMD
Novartis has secured the US Food and Drug Administration (FDA) approval for the use of its Beovu (brolucizumab) medicine to treat wet age-related macular degeneration (AMD).
Detecting Integrity Breaches in Pharmaceutical Blister Packaging
Demonstrating the integrity of pharmaceutical blister packs is critically important, as any defects can affect the shelf life and efficacy of the contents.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.